The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2023 and forecasted to 2032

As per The Business Research Company’s Grand Mal Seizure Treatment Global Market Report 2023, the grand mal seizure treatment market is expected to show significant growth in the forecast period.

Key insights from the grand mal seizure treatment market forecast include:

1. Market Size

The global grand mal seizure treatment market is expected to grow from $1.81 billion in 2022 to $1.91 billion in 2023 at a compound annual growth rate (CAGR) of 5.9%. The grand mal seizure treatment market is expected to reach $2.34 billion in 2027 at a CAGR of 5.2%.

2. Major Driver

The high prevalence of epilepsy is expected to propel the growth of the grand mal seizure treatment market going forward. For instance, in February 2023, according to the World Health Organization, a Switzerland-based public health agency of the United Nations, approximately 50 million people in the world were suffering from epilepsy, making it one of the most prevalent neurological conditions worldwide. Every year, about 5 million people are diagnosed with epilepsy. Therefore, the high prevalence of epilepsy is driving the growth of the grand mal seizure treatment market.

View More On The Grand Mal Seizure Treatment Market Report 2023 – https://www.thebusinessresearchcompany.com/report/grand-mal-seizure-treatment-global-market-report

3. Key Trend

The development of novel treatments is a key trend gaining popularity in the grand mal seizure treatment market. Major companies operating in the grand mal seizure treatment market are developing novel treatment options For instance, in November 2020, UCB Inc., a Belgium-based biopharmaceutical company, announced the U.S. Food and Drug Administration (FDA) approval of VIMPAT [®] (lacosamide) CV in the US as an adjunctive therapy to treat patients four years of age and older who have primary generalized tonic-clonic seizures (PGTCS). The three forms of VIMPAT include intravenous (IV) injections, oral tablets, and oral solutions. All three VIMPAT formulations, including the injectable for intravenous administration, are now approved for the management of PGTCS in patients four years of age and older and for the treatment of partial-onset seizures. These approvals support UCB’s innovation in modernizing epilepsy care while providing more assistance to epileptic patients who may have previously had few treatment alternatives.

4. Largest Region

North America was the largest region in the grand mal seizure treatment market in 2022.

5. Major Players

Major players in the grand mal seizure treatment market are Pfizer Inc., Johnson & Johnson Inc., Novartis AG, Sanofi S.A., GlaxoSmithKline PLC, Takeda Pharmaceuticals Inc., Mylan N.V., UCB Celltech Ltd., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Lupin Pharmaceuticals Inc., Dr. Reddy’s Laboratories Ltd., Cipla Inc., Apotex Inc., Hikma Pharmaceuticals PLC, Alkem Laboratories Ltd., Jubilant Life Sciences Limited, Torrent Pharmaceuticals Ltd., Zydus Cadila, Strides Pharma Science Limited, Glenmark Pharmaceuticals Ltd., Wockhardt Ltd., Macleods Pharmaceuticals Ltd., Intas Pharmaceuticals Ltd., Alembic Pharmaceuticals Limited, Indoco Remedies Limited, and Spectrum Chemical Mfg. Corp.

Request A Sample Of The Global Grand Mal Seizure Treatment Market Report 2023:
https://www.thebusinessresearchcompany.com/sample_request?id=12349&type=smp

Key Grand Mal Seizure Treatment Market Segments
The global grand mal seizure treatment market is segmented –
1) By Type: Barbiturates, Hydantoin, Phenyltriazine, Iminostilbenes, Benzodiazepines, Aliphatic Carboxylic Acids, Other Types
2) By Diagnosis: Magnetic Resonance Imaging (MRI), Electroencephalogram (EEG), Blood Tests, Computed Tomography (CT), Other Diagnosis
3) By Treatment: Antiepileptic Drugs, Surgery, Vagus Nerve Stimulation, Ketogenic Diet, Other Treatments
4) By End Users: Academic And Research Centers, Neurological Centers, Hospitals, Other End Users

The Grand Mal Seizure Treatment Global Market Report 2023  provides an in-depth analysis on the grand mal seizure treatment market size, trends and drivers, opportunities, strategies, and companies analysis. The countries covered in the grand mal seizure treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA, and the major seven regions are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

View More Related Reports –
Generic Central Nervous System Drugs Global Market Report 2023
Computed Tomography (CT) Scanners Devices And Equipment Global Market Report 2023
Brain Monitoring Global Market Report 2023

Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]

Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model